GSK divested these product candidates to satisfy antitrust requirements for the (completed) asset swap with NVS announced last year. GSK still owns the marketed Menveo and Bexsero meningitis vaccines acquired in the NVS asset swap.
Oddly (in terms of the antitrust perspective), PFE already owns a meningitis vaccine called Trumenba that is similar to Bexsero.